Prexa Pharmaceuticals
Prexa Pharmaceuticals develops small molecule monoamine reuptake inhibitors as a treatment for ADHD, depression and Parkinson’s disease.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD43—65m (Dealroom.co estimates May 2011.)
Boston Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$7.0m | Series B | ||
| Total Funding | AUD10.8m | ||